165 related articles for article (PubMed ID: 21857867)
1. Capacity building for assessing new technologies: approaches to examining personalized medicine in practice.
Van Bebber SL; Trosman JR; Liang SY; Wang G; Marshall DA; Knight S; Phillips KA
Per Med; 2010 Jul; 7(4):427-439. PubMed ID: 21857867
[TBL] [Abstract][Full Text] [Related]
2. Health technology assessment and private payers' coverage of personalized medicine.
Trosman JR; Van Bebber SL; Phillips KA
J Oncol Pract; 2011 May; 7(3 Suppl):18s-24s. PubMed ID: 21886515
[TBL] [Abstract][Full Text] [Related]
3. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
4. Health technology assessment and private payers's coverage of personalized medicine.
Trosman JR; Van Bebber SL; Phillips KA
Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP53-60. PubMed ID: 21711078
[TBL] [Abstract][Full Text] [Related]
5. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.
Trosman JR; Weldon CB; Douglas MP; Deverka PA; Watkins JB; Phillips KA
Value Health; 2017 Jan; 20(1):40-46. PubMed ID: 28212967
[TBL] [Abstract][Full Text] [Related]
6. Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay.
Trosman JR; Van Bebber SL; Phillips KA
J Oncol Pract; 2010 Sep; 6(5):238-42. PubMed ID: 21197187
[TBL] [Abstract][Full Text] [Related]
7. Payer perceptions on the use of patient-reported outcomes in oncology decision making.
Oderda G; Brixner D; Biskupiak J; Burgoyne D; Arondekar B; Deal LS; Quek RG; Niyazov A
J Manag Care Spec Pharm; 2022 Feb; 28(2):188-195. PubMed ID: 34806908
[No Abstract] [Full Text] [Related]
8. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
Deverka PA; Douglas MP; Phillips KA
Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
[TBL] [Abstract][Full Text] [Related]
9. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
[TBL] [Abstract][Full Text] [Related]
10. Payer view of personalized medicine.
Pezalla EJ
Am J Health Syst Pharm; 2016 Dec; 73(23):2007-2012. PubMed ID: 27864208
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Bridging the Gaps in Personalized Medicine Value Assessment: A Review of the Need for Outcome Metrics across Stakeholders and Scientific Disciplines.
Bush WS; Cooke Bailey JN; Beno MF; Crawford DC
Public Health Genomics; 2019; 22(1-2):16-24. PubMed ID: 31454805
[TBL] [Abstract][Full Text] [Related]
13. Strengthening Multipayer Collaboration: Lessons From the Comprehensive Primary Care Initiative.
Anglin G; Tu HA; Liao K; Sessums L; Taylor EF
Milbank Q; 2017 Sep; 95(3):602-633. PubMed ID: 28895218
[TBL] [Abstract][Full Text] [Related]
14. Payer perceptions on the use of economic models in oncology decision making.
Biskupiak J; Oderda G; Brixner D; Burgoyne D; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Nov; 27(11):1560-1567. PubMed ID: 34714111
[No Abstract] [Full Text] [Related]
15. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research.
O'Donnell JC
Value Health; 2013; 16(6 Suppl):S1-3. PubMed ID: 24034305
[TBL] [Abstract][Full Text] [Related]
16. Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU-actions for stakeholders.
Facey KM; Rannanheimo P; Batchelor L; Borchardt M; de Cock J
Int J Technol Assess Health Care; 2020 Sep; ():1-10. PubMed ID: 32878663
[TBL] [Abstract][Full Text] [Related]
17. Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment.
Dhanda DS; Veenstra DL; Regier DA; Basu A; Carlson JJ
J Manag Care Spec Pharm; 2020 Apr; 26(4):529-537. PubMed ID: 32223606
[TBL] [Abstract][Full Text] [Related]
18. A review of international coverage and pricing strategies for personalized medicine and orphan drugs.
Degtiar I
Health Policy; 2017 Dec; 121(12):1240-1248. PubMed ID: 29033060
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
